Last checked at (Sharecast News) - Point-of-care business EKF Diagnostics said on Monday that it looked set to trade ahead of market expectations for the full year.
EKF cited strong trading in October, combined with expected orders for the remainder of the year, for driving its 2020 performance ahead of market expectations, which had already been revised upwards several times during the year.
The AIM-listed firm now expects to deliver group revenues and adjusted underlying earnings "comfortably ahead" of market consensus of £60.0m and £23.0m, respectively.
EKF said the performance was driven by "significantly improved" trading in the group's core business in the final quarter, along with continued orders for its PrimeStore MTM Covid-19 sample collection device.
As of 1015 GMT, EKF shares were up 1.61% at 78.75p.
26 Nov 2020 14:53
EKF partner Kantaro gets FDA authorisation for Covid-19 test
(Sharecast News) - Point-of-care company EKF Diagnostics updated the market on developments at its partner Kantaro Biosciences on Thursday, confirming that it had received Emergency Use Authorization from the US Food and Drug Administration (FDA) for 'COVID-SeroKlir', its semi-quantitative SARS-CoV-2 IgG antibody test kit.
Read more